RDY - Dr. Reddy's Laboratories Ltd

...

Available for logged in users only.

The multiple price alert feature will smartly add or remove $1 if your alert was hit.
It's only available if you are logged in, a V.I.P. member or if you are using the AI chrome extension.

Contact us via Twitter if you are interested in trying it out.

• GSK says Canadian court dismisses potential Zantac class suit
• Dr. Reddy's GAAP EPS of $0.70, revenue of $766M beats by $8.32M
• Dr. Reddy's launches generic version of Astellas' Lexiscan in US
• Dr. Reddy's launches generic version of hypertension drug Remodulin in US
• Aditxt stock rises ~10% on plans to buy 50% stake in Global Response Aid from Cellvera
• GSK stock falls after California court ruling on Zantac; company disagrees with decision
• Dr. Reddy's to acquire U.S. generic portfolio of Mayne Pharma
• Dr. Reddy's GAAP EPS of $0.91, revenue of $818M
• Dr. Reddy's prepare to file for Rituxan biosimilar in US, EU as trials completed
• GSK ready to defend claims at state level after federal judge dismisses Zantac suits
• Why did Sanofi stock jump up today? Zantac litigation tossed out by judge
• GSK, Sanofi, Haleon jump after win in Zantac product liability case
• Off-patent drugs make up 91% of prescriptions, but only 18% of spending - report
• Sanofi, GSK gains as Citi sees limited impact from Zantac claims
• Intercept, Dr. Reddy’s settle patent dispute over Oclaiva generics
• Teva, Perrigo drop after settlements for dismissal of Zantac trial
• Athenex soars 70% as Dr Reddy's and Intas race to form buyout deal
• Dr. Reddy's GAAP EPS of $0.90, revenue of $660M misses by $12.78M
• Dr. Reddy's Q1 2023 Earnings Preview
• Dr. Reddy's launches generic of Takeda's cancer drug Velcade in US